{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:58:16Z","timestamp":1793656696242,"version":"4.5.1"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Vascular cell adhesion molecule 1 (VCAM-1) and intracellular cell adhesion molecule 1 (ICAM-1) are responsible for immune cell-cell interactions. Systemic levels of VCAM-1 are associated with incident heart failure (HF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To determine if VCAM-1 and ICAM-1 levels are associated with progression of established HF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Participants enrolled in the biomarker substudy of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) randomized clinical trial had VCAM-1 and ICAM-1 levels measured at baseline and 12 months. The DAPA-HF trial was conducted at 410 sites in 20 countries. Patients with HF and reduced ejection fraction (HFrEF) in New York Heart Association (NYHA) class II to IV with elevated natriuretic peptides were enrolled between February 15, 2017, and August 17, 2018, with final follow-up on June 6, 2019. Data were analyzed from January 2023 to January 2025.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Dapagliflozin, 10 mg, once daily vs placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the composite of a worsening HF event or cardiovascular death. The associations between VCAM-1 and ICAM-1 levels at baseline and the primary outcome, its components, and all-cause death were analyzed using Cox proportional hazards regression models adjusted for known prognostic variables including estimated glomerular filtration rate (eGFR), N-terminal pro\u2013B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin T (hs-TnT), as well as high-sensitivity C-reactive protein.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 3051 participants (mean [SD] age, 67.2 [10.5] years; 2386 male [78.2%]) were included in this study. Mean (SD) follow-up time was 17.6 (5.2) months. The median (IQR) baseline VCAM-1 level was 997 (816.7-1218.8) ng\/mL. Compared with patients with lower concentrations of VCAM-1, those with higher concentrations of VCAM-1 were older (mean [SD] age T3 vs T1, 69.7\u2009[9.7] years vs 64.1\u2009[10.7] years; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), in worse NYHA class (T3 vs T1, NYHA class III\/IV 35.6% [362 of 1017] vs 26.5% [269 of 1017]; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001), and had higher NT-proBNP (median [IQR] T3 vs T1, 2018 [1126-3753] pg\/mL vs 1118 [693-1830] pg\/mL) and hs-TnT (median [IQR] T3 vs T1, 24.7 [17.1-37.5] ng\/L vs 16.6 [11.6-24.9] ng\/L) concentrations, and lower eGFR (mean [SD] T3 vs T1, 58.4 [17.6] mL\/min\/1.73 m<jats:sup>2<\/jats:sup> vs 71.7 [18.0] mL\/min\/1.73 m<jats:sup>2<\/jats:sup>). Patients in tertile 3 of VCAM-1, compared with tertile 1, had the highest risk of each outcome (eg, adjusted hazard ratio [HR] for primary outcome 1.40; 95% CI, 1.11-1.77; <jats:italic>P<\/jats:italic>\u2009=\u2009.004). ICAM-1 level was not associated with an elevated risk of any outcome. The benefit of dapagliflozin vs placebo in reducing the risk of the primary outcome was consistent across VCAM-1 tertiles: HR, 0.76 (95% CI, 0.54-1.06), 0.82 (95% CI, 0.59-1.12), and 0.77 (95% CI, 0.61-0.98) for tertiles 1, 2 and 3, respectively (<jats:italic>P<\/jats:italic> for interaction\u2009=\u2009.93). There was no significant change in VCAM-1 level with dapagliflozin at 52 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Results of this substudy of the DAPA-HF randomized clinical trial demonstrate that higher VCAM-1 levels, possibly reflecting a distinct inflammatory\/immune pathophysiological pathway in HFrEF, were associated with worse outcomes, even after adjustment for conventional prognostic variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03036124\">NCT03036124<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2025.1592","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T11:00:30Z","timestamp":1749034830000},"page":"797","source":"Crossref","is-referenced-by-count":14,"title":["Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure"],"prefix":"10.1001","volume":"10","author":[{"given":"Kirsty","family":"McDowell","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Welsh","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Morrow","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, TIMI Study Group, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"De Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus Medical Centre, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"O\u2019Meara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Montreal Heart Institute, University de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Section of Endocrinology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, University of Missouri-Kansas City, Kansas City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Instituto DAMIC, Cordoba National University, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hammarstedt","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, TIMI Study Group, Boston, Massachusetts"},{"name":"Deputy Editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"hoi250026r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114471","article-title":"Cell adhesion molecule-mediated therapeutic strategies in atherosclerosis: from a biological basis and molecular mechanism to drug delivery nanosystems.","volume":"186","author":"Yin","year":"2021","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"hoi250026r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2021.166170","article-title":"VCAM-1 as a predictor biomarker in cardiovascular disease.","volume":"1867","author":"Troncoso","year":"2021","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"hoi250026r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.104802","article-title":"Novel insights on the role of VCAM-1 and ICAM-1: potential biomarkers for cardiovascular diseases.","volume":"84","author":"Kaur","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"issue":"1","key":"hoi250026r4","doi-asserted-by":"publisher","first-page":"19488","DOI":"10.1038\/s41598-021-98998-3","article-title":"VCAM1 expression in the myocardium is associated with the risk of heart failure and immune cell infiltration in myocardium.","volume":"11","author":"Wang","year":"2021","journal-title":"Sci Rep"},{"issue":"11","key":"hoi250026r5","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/eurheartj\/ehp046","article-title":"Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles.","volume":"30","author":"Goette","year":"2009","journal-title":"Eur Heart J"},{"issue":"4","key":"hoi250026r6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction.","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"22","key":"hoi250026r7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019390","article-title":"Circulating vascular cell adhesion molecule-1 and incident heart failure: the Multi-Ethnic Study of Atherosclerosis (MESA).","volume":"9","author":"Patel","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"hoi250026r8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S1388-9842(03)00009-6","article-title":"The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure.","volume":"5","author":"Yin","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hoi250026r9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcla.21570","article-title":"The role of serum VCAM-1 and TNF-a as predictors of mortality and morbidity in patients with chronic heart failure.","volume":"27","author":"Savic-Radojevic","year":"2013","journal-title":"J Clin Lab Anal"},{"issue":"21","key":"hoi250026r10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi250026r11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced proinflammatory-oxidative pathways and protein kinase Ga oxidation.","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"3","key":"hoi250026r12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/bimj.200710415","article-title":"Youden Index and optimal cut point estimated from observations affected by a lower limit of detection.","volume":"50","author":"Ruopp","year":"2008","journal-title":"Biom J"},{"issue":"10","key":"hoi250026r13","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.","volume":"30","author":"Uno","year":"2011","journal-title":"Stat Med"},{"issue":"3","key":"hoi250026r14","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1093\/ndt\/gfx256","article-title":"Glomerular function in relation to circulating adhesion molecules and inflammation markers in a general population.","volume":"33","author":"Feng","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"hoi250026r15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41366-020-00667-4","article-title":"Circulating cell adhesion molecules in metabolically healthy obesity.","volume":"45","author":"Mulhem","year":"2021","journal-title":"Int J Obes (Lond)"},{"issue":"5","key":"hoi250026r16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamacardio.2017.0064","article-title":"Association between vascular cell adhesion molecule 1 and atrial fibrillation.","volume":"2","author":"Willeit","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi250026r17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s003920050158","article-title":"Zirkulierende adh\u00e4sionsmolek\u00fcle (cICAM-1, cVCAM-1) bei patienten mit verdacht auf entz\u00fcndliche herzmuskelerkrankungen.","volume":"87","author":"Klein","year":"1998","journal-title":"Zeitschrift f\u00fcr Kardiologie"},{"issue":"5","key":"hoi250026r18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/S0002-9149(97)00972-7","article-title":"Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation.","volume":"81","author":"Andreassen","year":"1998","journal-title":"Am J Cardiol"},{"issue":"6","key":"hoi250026r19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation.","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"issue":"6","key":"hoi250026r20","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/0092-8674(89)90775-7","article-title":"Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes.","volume":"59","author":"Osborn","year":"1989","journal-title":"Cell"},{"key":"hoi250026r21","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.amjcard.2022.05.026","article-title":"Neutrophils and circulating inflammatory biomarkers in diabetes mellitus and heart failure with preserved ejection fraction.","volume":"178","author":"Chaar","year":"2022","journal-title":"Am J Cardiol"},{"issue":"4","key":"hoi250026r22","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.cardfail.2023.07.016","article-title":"Experimentally induced peripheral venous congestion exacerbates inflammation, oxidative stress, and neurohormonal and endothelial cell activation in patients with systolic heart failure.","volume":"30","author":"Colombo","year":"2024","journal-title":"J Card Fail"},{"issue":"48","key":"hoi250026r23","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme.","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"issue":"20","key":"hoi250026r24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/j.jacc.2024.07.013","article-title":"Reaffirmation of mechanistic proteomic signatures accompanying SGLT2 inhibition in patients with heart failure: a validation cohort of the EMPEROR program.","volume":"84","author":"Packer","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"hoi250026r25","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1182\/blood-2006-03-006759","article-title":"Targeted gene deletion demonstrates that the cell adhesion molecule ICAM-4 is critical for erythroblastic island formation.","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"issue":"2","key":"hoi250026r26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/path.2396","article-title":"Expression of EpCAM is up-regulated during regeneration of renal epithelia.","volume":"216","author":"Trzpis","year":"2008","journal-title":"J Pathol"},{"issue":"3","key":"hoi250026r27","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S0735-1097(99)00594-X","article-title":"Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure.","volume":"35","author":"Tsutamoto","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"hoi250026r28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1058268","article-title":"Blocking VCAM-1 ameliorates hypertensive cardiac remodeling by impeding macrophage infiltration.","volume":"13","author":"Qiu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"hoi250026r29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.atherosclerosis.2004.08.037","article-title":"Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure.","volume":"178","author":"Tousoulis","year":"2005","journal-title":"Atherosclerosis"},{"issue":"2","key":"hoi250026r30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00392-018-1331-2","article-title":"T-cell and monocyte\/macrophage activation markers associate with adverse outcome but give limited prognostic value in anemic patients with heart failure: results from RED-HF.","volume":"108","author":"Abraityte","year":"2019","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"hoi250026r31","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003126","article-title":"Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure.","volume":"5","author":"Salvador","year":"2016","journal-title":"J Am Heart Assoc"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2835023\/jamacardiology_mcdowell_2025_oi_250026_1754420631.98608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T15:00:56Z","timestamp":1755097256000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2835023"}},"subtitle":["Findings From the DAPA-HF Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2025.1592","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}